Kohjin Bio Co.,Ltd. (177A) AI Stock Analysis

• Market Cap: ¥6.37B
• Dividend Yield: 1.62%
• Average Volume (3M): 3.64K
• Price to Earnings (P/E): 11.4
• Beta (1Y): 0.86
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: JP
• Employees: 159
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 15.18
• Shares Outstanding: 5,111,600
• 10 Day Avg. Volume: 4,170
• 30 Day Avg. Volume: 3,643
• PEG Ratio: 0.16
• Price to Book (P/B): 1.55
• Price to Sales (P/S): 1.72
• P/FCF Ratio: 318.77
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 67 Neutral
• Price Target: ¥1,352.00 ▼(-11.34% Downside)
• Action: Downgraded Date: 10/30/25
• Date: Action: Downgraded 10/30/25

Kohjin Bio Co., Ltd. shows strong financial performance with robust growth in revenue and profitability, supported by a stable balance sheet. However, the technical indicators suggest a bearish trend, which could pose short-term risks. The valuation is reasonable, with a moderate P/E ratio and dividend yield, making it attractive for long-term investors. The absence of recent earnings call insights or notable corporate events limits additional context.

Positive Factors

Balance Sheet Strength

High equity ratio and low leverage provide durable financial resilience, reducing refinancing and solvency risk. A 13.75% ROE signals efficient capital deployment, supporting the company's ability to fund R&D, operations or acquisitions without excessive debt over the medium term.

Healthy Profitability and Margins

Sustained high gross and operating margins indicate structural pricing power and operational efficiency versus peers. Robust EBIT/EBITDA margins create durable cash generation capacity, allowing reinvestment in product development and a cushion against sector margin pressure.

Strong Operating Cash Conversion Trend

Operating cash flow exceeding net income shows earnings quality and cash conversion discipline, while positive free cash flow growth signals improving liquidity. Together these trends support sustainable funding for capex, R&D and debt reduction over coming quarters.

Negative Factors

Low Free Cash Flow Conversion

Very low FCF-to-income limits financial flexibility despite good operating cash metrics; it constrains capacity for dividends, buybacks or large reinvestments. Structural improvement in working capital or lower capex is needed to translate profits into durable distributable cash.

Negative EPS Growth

A steep drop in EPS growth signals potential pressure on per-share profitability or one-off impacts that dent returns to shareholders. Persisting negative EPS trends would undermine reinvestment capacity and make earnings sustainability uncertain over the medium term.

Inconsistent Revenue Trend

Mixed revenue metrics indicate inconsistency in top-line performance or timing effects across reporting periods. Revenue volatility reduces predictability for planning R&D, capacity and commercial expansion, complicating long-term forecasting and strategic investment choices.

Kohjin Bio Co.,Ltd. Business Overview & Revenue Model

Company Description

Kohjin Bio Co., Ltd. is a biotechnology company specializing in the development and production of bioactive compounds and fermentation products. The company operates primarily in the health and wellness sectors, focusing on nutritional supplements, functional foods, and pharmaceutical intermediates. Kohjin Bio is known for its innovative approaches to biotechnology, leveraging fermentation technology to create high-quality, bioavailable ingredients that cater to a growing market for health-conscious consumers.

How the Company Makes Money

Kohjin Bio generates revenue through multiple key streams, including the sale of proprietary bioactive ingredients and fermentation products to manufacturers in the dietary supplement and functional food sectors. The company engages in business-to-business transactions, supplying its products to other companies that incorporate these ingredients into their own offerings. Additionally, Kohjin Bio may generate income through research and development partnerships with larger pharmaceutical or nutraceutical companies, providing expertise and technology in exchange for funding or royalties. The company's commitment to innovation and high-quality production processes allows it to maintain competitive pricing and establish long-term relationships with clients, contributing significantly to its earnings.

Kohjin Bio Co.,Ltd. Financial Statement Overview

Summary

Kohjin Bio Co., Ltd. demonstrates robust financial health with strong growth in revenue and profitability, supported by a stable balance sheet. Effective leverage management and profitability metrics point to a solid operational footing. While cash flow generation is improving, enhancing free cash flow remains a focus area to bolster financial resilience further.

Income Statement

Kohjin Bio Co., Ltd. shows a strong revenue growth rate of 9.14% from 2024 to 2025 and a notable increase in net income, indicating positive momentum. The gross profit margin stands at 45.44%, and the net profit margin improved to 15.26%, reflecting efficient cost management. EBIT and EBITDA margins are also healthy, at 19.04% and 27.01%, respectively, suggesting robust profitability. However, the volatility in EBIT over the years indicates some operational fluctuations.

Balance Sheet

The company's balance sheet reflects stability with a solid equity ratio of 63.78%, indicating a strong capitalization. The debt-to-equity ratio has improved to 0.41, which suggests effective leverage management. Return on Equity (ROE) is impressive at 13.75%, demonstrating efficient use of shareholder funds. Despite these strengths, the company needs to maintain vigilance over its debt levels to ensure sustained financial stability.

Cash Flow

Operating cash flow is strong, with a good ratio of operating cash flow to net income at 1.15, indicating efficient cash conversion. Free cash flow to net income ratio is 0.04, showing modest free cash flow generation. However, the free cash flow growth rate of 7.52% indicates improvement, though further enhancements in cash generation would strengthen financial flexibility.

Breakdown	TTM	Mar 2025	Mar 2025	Mar 2023	Mar 2022
Income Statement
Total Revenue	5.18B	5.21B	4.77B	4.74B	3.95B
Gross Profit	2.31B	2.37B	1.88B	2.45B	2.04B
EBITDA	1.26B	1.41B	958.10M	1.44B	1.14B
Net Income	714.00M	794.76M	384.00M	829.79M	587.67M
Balance Sheet
Total Assets	9.17B	9.07B	6.59B	6.13B	5.60B
Cash, Cash Equivalents and Short-Term Investments	3.10B	3.15B	1.73B	1.46B	1.73B
Total Debt	1.99B	2.39B	2.47B	2.10B	2.23B
Total Liabilities	3.46B	3.28B	3.25B	3.12B	3.38B
Stockholders Equity	5.71B	5.78B	3.34B	3.02B	2.22B
Cash Flow
Free Cash Flow	0.00	28.05M	260.88M	-99.57M	559.44M
Operating Cash Flow	0.00	915.55M	823.68M	461.15M	762.98M
Investing Cash Flow	0.00	-1.09B	-577.35M	-575.46M	82.78M
Financing Cash Flow	0.00	1.38B	-1.35M	-172.21M	-360.17M

Kohjin Bio Co.,Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1525.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:177A, the sentiment is Neutral. The current price of 1525 is above the 20-day moving average (MA) of 1216.95, above the 50-day MA of 1338.38, and below the 200-day MA of 1562.12, indicating a neutral trend. The MACD of -31.04 indicates Negative momentum. The RSI at 46.81 is Neutral, neither overbought nor oversold. The STOCH value of 39.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:177A.

Kohjin Bio Co.,Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
177A	67 Neutral	¥6.37B	11.43	―	1.62%	―	―
4978	59 Neutral	¥17.82B	-54.84	―	―	1.24%	-33.41%
7774	54 Neutral	¥32.33B	-70.05	―	―	-5.65%	-469.19%
4974	52 Neutral	¥138.12B	-19.18	―	2.18%	-0.16%	-802.20%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
7776	49 Neutral	¥14.17B	-11.63	―	―	-42.49%	-2.37%
4599	43 Neutral	¥19.24B	-10.06	―	―	―	11.34%